← Leaderboards
Patricia Leal Dahia
University Of Texas Hlth Science Center
$3,076,073
Attributed
$4,666,041
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $822.6K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,666,041 · 2
By mechanism
R01$4,666,041 · 2
Top collaborators
- Alice Soragni10 shared
Others in their field
Other Emerging Leaders on “Neuroendocrine Tumors”
- Himisha Beltran · Dana-Farber Cancer Inst$7,515,798
- Michael King Schultz · Viewpoint Molecular Targeting, Inc.$6,896,677
- Joseph Grudzinski · Voximetry, Inc.$4,969,457
- Paul Wickre · Voximetry, Inc.$3,377,635
- Aatur Dilip Singhi · University Of Pittsburgh At Pittsburgh$2,897,842
- Boyang Wu · Washington State University$2,875,229
Research focus
Neuroendocrine TumorsInsightPheochromocytomaNovel TherapeuticsPropertyDesignTumorPrimary NeoplasmCellsMalignant NeoplasmsDiagnosisBiologyPharmaceutical PreparationsBiological ModelsInvestigationOrganoidsNeuroendocrine CancerEffective TherapyFutureBiologicalExperimental ModelsGeneticDrug ScreeningNeoplasm Metastasis
Grant awards (15)
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$497,187
R01 · FY2025 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$237,198
R01 · FY2025 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$74,115
R01 · FY2025 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$468,662
R01 · FY2024 · CA · contact PI
Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid models$265,946
R01 · FY2024 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$70,409
R01 · FY2024 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$483,461
R01 · FY2023 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$74,115
R01 · FY2023 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$483,461
R01 · FY2022 · CA · contact PI
Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model$525,382
R01 · FY2021 · CA · contact PI
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex$297,221
R01 · FY2021 · GM · contact PI
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex$297,221
R01 · FY2020 · GM · contact PI
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex$297,221
R01 · FY2019 · GM · contact PI
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex$297,221
R01 · FY2018 · GM · contact PI
Interaction of the TMEM127 tumor suppressor with the mTORC1 lysosomal activating complex$297,221
R01 · FY2017 · GM · contact PI